Por: The Hill Health May 15, 2023
Patients, lawmakers and Alzheimer’s advocates are pushing for Medicare to fully cover a new drug for treating early stage Alzheimer’s. The Food and Drug Administration (FDA) granted accelerated approval to Eisai’s Alzheimer’s drug Leqembi in January. The drug has been shown to moderately slow the progression of the disease in its early stages. “So there’s a sense of desperation really for me and for others out there that... + full article
CNBC USA Health February 24, 2023
The Alzheimer's drug LEQEMBI is seen in this undated handout image obtained by Reuters on January 20, 2023.Eisai via ReutersMedicare will not provide broader coverage of the Alzheimer's drug Leqembi until it receives more evidence that the treatment is reasonable and... + más
Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage | CNBC
Why a new Alzheimer's drug is having a slow US debut | ABC News
CNBC USA Health February 17, 2023
In this articleTek Image/science Photo Library Science Photo Library Getty ImagesJapanese drugmaker expects the Food and Drug Administration to fully approve its Alzheimer's treatment Leqembi this summer, which would expand access to the pricey new antibody under... + más
Medicare rejects Alzheimer's Association request for unrestricted coverage of treatments like Leqembi | CNBC
A new Alzheimer’s drug has been approved. What to know about lecanemab | Orlando Sentinel
ABC News USA Business February 04, 2023
The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. Two big factors behind the slow debut, experts say, are scant insurance coverage and a long setup time needed by many systems.Patients who surmount those... + más
How To Spot The Early Signs Of Alzheimer's | Newsweek
Here's what disease does to brain, signs to look for: Alzheimer's Q&A | The Advocate
WPLG Local 10 USA Health February 04, 2023
The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. Two big factors behind the slow debut, experts say, are scant insurance coverage and a long setup time needed by many health systems.Patients who surmount... + más
Associated Press USA Health February 04, 2023
Orlando Sentinel USA Nation January 17, 2023
A new drug that appears to slow early Alzheimer’s disease is coming to the market. The Food and Drug Administration on Friday approved lecanemab, which will be marketed as Leqembi, for public use. The decision comes after data published in The New England Journal of Medicine... + más
Reimagining Alzheimer’s (Part 4): Cautious Optimism For A New Alzheimer’s Disease Treatment | Forbes
5 things to know about the new Alzheimer’s drug — including why it may be risky for people who take blood thinners | MarketWatch
Forbes USA Business January 09, 2023
Conceptual illustration showing an elderly person with progressive impairments of brain functions.getty The for the anti-Alzheimer’s drug lecanemab, which will be sold as Leqembi, has significant potential for research into treatment of the disease. But people living with... + más
What Are the Duties of A Trustee? | Forbes
About iurex | Privacy Policy | Disclaimer |